Amgen Inc.Long
Seems like a strong breakout for $AMGN
Symbol: AMGN
AssetType: Common Stock
Name: Amgen Inc
Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Exchange: NASDAQ
Currency: USD
Country: USA
Sector: Healthcare
Industry: Drug Manufacturers-General
Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
FullTimeEmployees: 23400
FiscalYearEnd: December
LatestQuarter: 2020-09-30
MarketCapitalization: 142916681728
EBITDA: 12647000064
PERatio: 19.7992
PEGRatio: 1.5407
BookValue: 18.781
DividendPerShare: 7.04
DividendYield: 0.0287
EPS: 12.399
RevenuePerShareTTM: 42.405
ProfitMargin: 0.2942
OperatingMarginTTM: 0.3757
ReturnOnAssetsTTM: 0.0945
ReturnOnEquityTTM: 0.6718
RevenueTTM: 24987000832
GrossProfitTTM: 19006000000
DilutedEPSTTM: 12.399
QuarterlyEarningsGrowthYOY: 0.049
QuarterlyRevenueGrowthYOY: 0.12
AnalystTargetPrice: 255.28
TrailingPE: 19.7992
ForwardPE: 13.7741
PriceToSalesRatioTTM: 5.5562
PriceToBookRatio: 12.4317
EVToRevenue: 6.4341
EVToEBITDA: 12.4492
Beta: 0.7616
52WeekHigh: 261.431
52WeekLow: 173.5108
50DayMovingAverage: 229.69
200DayMovingAverage: 238.9139
SharesOutstanding: 582169024
SharesFloat: 581126530
SharesShort: 6958047
SharesShortPriorMonth: 6912555
ShortRatio: 2.82
ShortPercentOutstanding: 0.01
ShortPercentFloat: 0.012
PercentInsiders: 0.188
PercentInstitutions: 77.988
ForwardAnnualDividendRate: 7.04
ForwardAnnualDividendYield: 0.0287
PayoutRatio: 0.3993
DividendDate: 2021-03-08
ExDividendDate: 2021-02-11
LastSplitFactor: 2:1
LastSplitDate: 1999-11-22
AssetType: Common Stock
Name: Amgen Inc
Description: Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Exchange: NASDAQ
Currency: USD
Country: USA
Sector: Healthcare
Industry: Drug Manufacturers-General
Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
FullTimeEmployees: 23400
FiscalYearEnd: December
LatestQuarter: 2020-09-30
MarketCapitalization: 142916681728
EBITDA: 12647000064
PERatio: 19.7992
PEGRatio: 1.5407
BookValue: 18.781
DividendPerShare: 7.04
DividendYield: 0.0287
EPS: 12.399
RevenuePerShareTTM: 42.405
ProfitMargin: 0.2942
OperatingMarginTTM: 0.3757
ReturnOnAssetsTTM: 0.0945
ReturnOnEquityTTM: 0.6718
RevenueTTM: 24987000832
GrossProfitTTM: 19006000000
DilutedEPSTTM: 12.399
QuarterlyEarningsGrowthYOY: 0.049
QuarterlyRevenueGrowthYOY: 0.12
AnalystTargetPrice: 255.28
TrailingPE: 19.7992
ForwardPE: 13.7741
PriceToSalesRatioTTM: 5.5562
PriceToBookRatio: 12.4317
EVToRevenue: 6.4341
EVToEBITDA: 12.4492
Beta: 0.7616
52WeekHigh: 261.431
52WeekLow: 173.5108
50DayMovingAverage: 229.69
200DayMovingAverage: 238.9139
SharesOutstanding: 582169024
SharesFloat: 581126530
SharesShort: 6958047
SharesShortPriorMonth: 6912555
ShortRatio: 2.82
ShortPercentOutstanding: 0.01
ShortPercentFloat: 0.012
PercentInsiders: 0.188
PercentInstitutions: 77.988
ForwardAnnualDividendRate: 7.04
ForwardAnnualDividendYield: 0.0287
PayoutRatio: 0.3993
DividendDate: 2021-03-08
ExDividendDate: 2021-02-11
LastSplitFactor: 2:1
LastSplitDate: 1999-11-22
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.